Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

VYNE Therapeutics (VYNE) Profit After Tax (2016 - 2025)

VYNE Therapeutics' Profit After Tax history spans 10 years, with the latest figure at -$5.8 million for Q2 2025.

  • For Q2 2025, Profit After Tax rose 38.74% year-over-year to -$5.8 million; the TTM value through Jun 2025 reached -$38.5 million, down 38.24%, while the annual FY2025 figure was -$26.7 million, 32.84% up from the prior year.
  • Profit After Tax reached -$5.8 million in Q2 2025 per VYNE's latest filing, up from -$8.6 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $17.6 million in Q4 2021 to a low of -$21.3 million in Q3 2021.
  • Average Profit After Tax over 5 years is -$7.6 million, with a median of -$8.4 million recorded in 2022.
  • Peak YoY movement for Profit After Tax: skyrocketed 175.71% in 2021, then plummeted 220.39% in 2023.
  • A 5-year view of Profit After Tax shows it stood at $17.6 million in 2021, then tumbled by 144.22% to -$7.8 million in 2022, then rose by 20.73% to -$6.2 million in 2023, then tumbled by 95.17% to -$12.0 million in 2024, then surged by 52.07% to -$5.8 million in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Profit After Tax are -$5.8 million (Q2 2025), -$8.6 million (Q1 2025), and -$12.0 million (Q4 2024).